🇺🇸 FDA

Intelligence · Clinical Pipeline

Eli Lilly and Pipeline

All ClinicalTrials.gov programs at Eli Lilly and — phase, modality, and trial IDs.

Programs
107

Quick answer

Eli Lilly and has 107 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. 0.9% sodium chloride, Lepodisiran

    Eli Lilly Co.

    Atherosclerotic Cardiovascular Disease Elevated lp(a)

    phase 3 small molecule active

    1 trial

  2. ABEMACICLIB , FULVESTRANT

    Eli Lilly Co.

    Breast cancer

    phase 3 small molecule active

    1 trial

  3. ANASTROZOLE , PALBOCICLIB , TERSOLISIB, RIBOCICLIB , EXEMESTANE , FULVESTRANT , abemaciclib, TERSOLISIB, TERSOLISIB, TERSOLISIB, LETROZOLE , TERSOLISIB, to match Tersolisib (LY4064809), STX-478

    Eli Lilly Co.

    Neoplasm Metastasis, Breast Neoplasms

    phase 3 small molecule active

    1 trial

  4. BARICITINIB, ADALIMUMAB, ADALIMUMAB, Baricitinib, BARICITINIB, BARICITINIB

    Eli Lilly Co.

    Uveitis

    phase 3 small molecule active

    1 trial

  5. BARICITINIB, BARICITINIB, Placebo to match LY, Baricitinib

    Eli Lilly Co.

    Diabetes Mellitus, Type 1

    phase 3 small molecule active

    1 trial

  6. BARICITINIB, Baricitinib, BARICITINIB, BARICITINIB

    Eli Lilly Co.

    Juvenile Idiopathic Arthritis

    phase 3 small molecule active

    1 trial

  7. BARICITINIB, Baricitinib, Placebo to match LY, BARICITINIB

    Eli Lilly Co.

    Diabetes Mellitus, Type 1

    phase 3 small molecule active

    1 trial

  8. BARICITINIB, TRIAMCINOLONE ACETONIDE, BARICITINIB, HYDROCORTISONE, Baricitinib, Placebo to match 4 mg tablet, BARICITINIB, HYDROCORTISONE, Hydrocutan Creme 1 %, Placebo to match 2mg tablet, Placebo to match 1mg tablet, Placebo to match 2mg/ml oral suspension

    Eli Lilly Co.

    Atopic Dermatitis

    phase 3 small molecule active

    1 trial

  9. Baricitinib

    Eli Lilly Co.

    Covid19 Corona Virus Infection

    phase 3 small molecule active

    1 trial

  10. Cabozantinib, SELPERCATINIB, VANDETANIB, SELPERCATINIB, Cabozantinib, CABOZANTINIB

    Eli Lilly Co.

    RET-Mutant Medullary Thyroid Cancer

    phase 3 small molecule active

    1 trial

  11. DULAGLUTIDE , Tirzepatide, Tirzepatide, Tirzepatide, Tirzepatide, Tirzepatide, Tirzepatide

    Eli Lilly Co.

    Type 2 Diabetes Mellitus

    phase 3 small molecule active

    1 trial

  12. Donanemab, Florbetapir F18, Flortaucipir F18, Flortaucipir, FLORBETAPIR, SODIUM CHLORIDE PH. EUR.

    Eli Lilly Co.

    Alzheimer Disease Dementia Brain Diseases Central Nervous System Diseases Nervous System Diseases Tauopathies Neurodegenerative Diseases Neurocognitive Disorders Mental Disorders

    phase 3 small molecule active

    1 trial

  13. EMPAGLIFLOZIN , DAPAGLIFLOZIN , INSULIN GLARGINE , Placebo to match LY3502970, METFORMIN

    Eli Lilly Co.

    Type 2 Diabetes

    phase 3 small molecule active

    1 trial

  14. Eloralintide, Eloralintide, Eloralintide, Placebo to match LY, Eloralintide

    Eli Lilly Co.

    Overweight, Obesity, Sleep Apnea, Obstructive

    phase 3 small molecule active

    1 trial

  15. Eloralintide, Eloralintide, Placebo to match LY, Eloralintide, Eloralintide

    Eli Lilly Co.

    Overweight, Obesity

    phase 3 small molecule active

    1 trial

  16. Eloralintide, Placebo to match LY, Eloralintide, Eloralintide, Eloralintide

    Eli Lilly Co.

    Obesity, Overweight

    phase 3 small molecule active

    1 trial

  17. FULVESTRANT , EXEMESTANE , ABEMACICLIB

    Eli Lilly Co.

    Breast Cancer

    phase 3 small molecule active

    1 trial

  18. GEMCITABINE , CARBOPLATIN , MIRVETUXIMAB SORAVTANSINE, TOPOTECAN , LY4170156, BEVACIZUMAB , PACLITAXEL , DOXORUBICIN

    Eli Lilly Co.

    Fallopian Tube Neoplasms, Peritoneal Neoplasms, Ovarian Neoplasms, Neoplasm Metastasis

    phase 3 small molecule active

    1 trial

  19. Galcanezumab, Placebo to match LY2951742

    Eli Lilly Co.

    Migraine

    phase 3 small molecule active

    1 trial

  20. Galcanezumab, Placebo to match LY2951742

    Eli Lilly Co.

    Chronic Migraine

    phase 3 small molecule active

    1 trial

  21. Lebrikizumab, MOMETASONE , Placebo for Lebrikizumab

    Eli Lilly Co.

    Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

    phase 3 small molecule active

    1 trial

  22. Lebrikizumab, Placebo for Lebrikizumab, MOMETASONE

    Eli Lilly Co.

    Perennial Allergic Rhinitis (PAR)

    phase 3 small molecule active

    1 trial

  23. METFORMIN , DAPAGLIFLOZIN

    Eli Lilly Co.

    Type 2 Diabetes

    phase 3 small molecule active

    1 trial

  24. Mirikizumab, Mirikizumab

    Eli Lilly Co.

    Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  25. Mirikizumab, Mirikizumab, Mirikizumab

    Eli Lilly Co.

    Crohn’s Disease

    phase 3 small molecule active

    1 trial

  26. Mirikizumab, Mirikizumab, Mirikizumab

    Eli Lilly Co.

    Crohn's Disease

    phase 3 small molecule active

    1 trial

  27. Mirikizumab, Tirzepatide, to match Tirzepatide, Tirzepatide, Tirzepatide, Mirikizumab, Tirzepatide, Tirzepatide, Tirzepatide

    Eli Lilly Co.

    Obesity or Overweight, Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  28. ORFORGLIPRON, ORFORGLIPRON, ORFORGLIPRON, ORFORGLIPRON, Orforglipron, Placebo to match LY, ORFORGLIPRON

    Eli Lilly Co.

    Hypertension

    phase 3 small molecule active

    1 trial

  29. Omvoh 300 mg concentrate for solution for infusion, Omvoh 100 mg solution for injection in pre-filled syringe

    Eli Lilly Co.

    Moderately to Severely Active Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  30. Orforglipron, Orforglipron, Orforglipron, Orforglipron, Orforglipron, Orforglipron, Placebo to match LY

    Eli Lilly Co.

    Osteoarthritis

    phase 3 small molecule active

    1 trial

  31. Orforglipron, Orforglipron, Orforglipron, Orforglipron, Placebo to match, Orforglipron, Orforglipron

    Eli Lilly Co.

    Chronic Kidney Disease, Atherosclerosis Cardiovascular Disease

    phase 3 small molecule active

    1 trial

  32. Orforglipron, Orforglipron, Orforglipron, Placebo to match ly, Orforglipron, Orforglipron, Orforglipron

    Eli Lilly Co.

    Peripheral Arterial Disease

    phase 3 small molecule active

    1 trial

  33. Orforglipron, Placebo to match LY, Orforglipron, Orforglipron, Orforglipron, Orforglipron, Orforglipron

    Eli Lilly Co.

    GZP1, GZP2: Obesity, Overweight GZP2: Type 2 Diabetes

    phase 3 small molecule active

    1 trial

  34. Orforglipron, Placebo to match LY3502970

    Eli Lilly Co.

    Obesity, Overweight

    phase 3 small molecule active

    1 trial

  35. PEMBROLIZUMAB , Placebo to match ly, ENFORTUMAB VEDOTIN

    Eli Lilly Co.

    Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis

    phase 3 small molecule active

    1 trial

  36. PREDNISOLONE , Verzenios 50 mg film-coated tablets, Placebo to match LY2835219 (Abemaciclib) Tablets, Placebo to match LY2835219 (Abemaciclib) Capsules, PREDNISONE , ABIRATERONE

    Eli Lilly Co.

    Prostate Cancer

    phase 3 small molecule active

    1 trial

  37. Placebo Injection, Retatrutide, Retatrutide, Retatrutide, Retatrutide, Retatrutide

    Eli Lilly Co.

    Overweight, Obesity

    phase 3 small molecule active

    1 trial

  38. Placebo to match 100mg tablet, Lasmiditan, LASMIDITAN, Placebo to match 50mg tablet, LASMIDITAN, Placebo to match 100mg film coated tablet, Lasmiditan, Placebo to match 25mg tablet, Lasmitidan, Placebo to match 50mg film coated tablet

    Eli Lilly Co.

    Migraine

    phase 3 small molecule active

    1 trial

  39. Placebo to match LY

    Eli Lilly Co.

    Overweight or Obesity, OSA (Obstructive Sleep Apnea)

    phase 3 small molecule active

    1 trial

  40. Placebo to match LY, Brenipatide, Brenipatide, Brenipatide

    Eli Lilly Co.

    Alcohol Use Disorder

    phase 3 small molecule active

    1 trial

  41. Placebo to match LY, Muvalaplin

    Eli Lilly Co.

    Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)

    phase 3 small molecule active

    1 trial

  42. Placebo to match LY, PEMBROLIZUMAB , DURVALUMAB

    Eli Lilly Co.

    Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  43. Placebo to match LY, Retatrutide, Retatrutide, Retatrutide, Retatrutide, Retatrutide

    Eli Lilly Co.

    Overweight, Chronic Low Back Pain (CLBP), Obesity

    phase 3 small molecule active

    1 trial

  44. Placebo to match LY3527723, Placebo to match LY3527723, SELPERCATINIB, SELPERCATINIB

    Eli Lilly Co.

    RET fusion-Positive NSCLC

    phase 3 small molecule active

    1 trial

  45. Placebo to match LY3537982, PEMBROLIZUMAB , PEMETREXED , CARBOPLATIN , CISPLATIN

    Eli Lilly Co.

    Stage IIIB-IIIC or Stage IV KRAS G12C-mutant non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  46. Placebo to match abemaciclib, Verzenios 50 mg film-coated tablets, FULVESTRANT

    Eli Lilly Co.

    Breast Neoplasm, Neoplasm Metastasis

    phase 3 small molecule active

    1 trial

  47. Placebo to match ly, Eloralintide, Eloralintide, Eloralintide, Eloralintide

    Eli Lilly Co.

    Obesity, Overweight

    phase 3 small molecule active

    1 trial

  48. Placebo to match ly, Orforglipron, Orforglipron, Orforglipron, Orforglipron, Orforglipron, Orforglipron

    Eli Lilly Co.

    Urinary Incontinence, Stress

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many pipeline programs does Eli Lilly and have?

107 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.